Traders Sell Gilead Sciences, Inc. (GILD) on Strength (GILD)

Xavier Trudeau
Août 17, 2017

The insider SCHOENHALS MARVIN N sold 15,900 shares worth $724,404. The Capital Management Corp holds 78,876 shares with $5.65M value, down from 97,226 last quarter.

Assetmark Inc. increased its position in shares of Gilead Sciences, Inc. The company's stock had a trading volume of 2,958,324 shares. (NASDAQ:GILD) has declined 21.80% since August 17, 2016 and is downtrending. It has underperformed by 38.50% the S&P500. Perritt Capital Management Inc, a Illinois-based fund reported 72,450 shares. Another trade for 1,716 shares valued at $99,528 was made by Boever Christopher J. on Friday, March 10. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping analysts' consensus estimates of $2.11 by $0.45.

GILD has been the subject of a number of research analyst reports. Insiders own 1.30% of the company's stock. The target implies a 17.37% spike from where the shares are now trading. About shares traded. ARC Group WorldWide Inc (ARCW) has risen 55.94% since August 17, 2016 and is uptrending. It has underperformed by 16.70% the S&P500. Its up 0.09, from 0.9 in 2016Q3.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. (NASDAQ:GILD) for 1,000 shares. Frontier Mgmt owns 64,100 shares or 0.44% of their United States portfolio. William Blair maintained Gilead Sciences, Inc. (GILD) now has a value of $73.35 while the company's 52 week low is at $63.76, the shares dropped to the 52 week low on 06/16/17. Following the sale, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. Barclays Public Ltd owns 4.45 million shares.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. (NASDAQ:GILD) or 577 shares. Shell Asset Management reported 122,649 shares stake. Japan-based Norinchukin Financial Bank The has invested 0.28% in Gilead Sciences, Inc. Neuberger Berman Gp Ltd Liability Com has invested 0.1% in Gilead Sciences, Inc. Moreover, Reynders Mcveigh Cap Ltd Liability Corp has 0.87% invested in Gilead Sciences, Inc. Alton Gregg H sold $337,392 worth of stock. MARTIN JOHN C also sold $4.78 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) earned "Hold" rating by BMO Capital Markets on Friday, July 21. (NASDAQ:GILD) news were published by: Fool.com which released: "The case for Gilead Sciences" on July 22, 2017, also Seekingalpha.com with their article: "Good News For Gilead's Bictegravir Regimen" published on August 15, 2017, Seekingalpha.com published: "Gilead's Newer Tenofovir Patents Might Aid Its HIV Franchise" on August 15, 2017. "Boosts Its Full-Year Outlook Thanks to Stronger-Than ..." published on July 26, 2017, Bizjournals.com published: "Why this Bay Area biotech giant chose SoCal for its new manufacturing plant" on August 16, 2017. More interesting news about Gilead Sciences, Inc.

Gilead Sciences, Inc. (NASDAQ:GILD) closed up +0.23 points or 0.31% at $73.35 with 5.22 mln shares exchanging hands. Therefore 63% are positive. World Fuel Services Corp had 10 analyst reports since July 31, 2015 according to SRatingsIntel.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. The firm earned "Buy" rating on Wednesday, October 28 by Maxim Group. Gilead Sciences's dividend payout ratio (DPR) is 22.58%. The rating was maintained by RBC Capital Markets with "Outperform" on Wednesday, February 3. That puts the market capitalization at $4.97 bln.

More notable recent Gilead Sciences, Inc. Maxim Group maintained it with "Buy" rating and $129 target in Wednesday, July 29 report. Gilead Sciences presently has an average rating of "Buy" and a consensus price target of $80.31. Bank of America upgraded the shares of CYBR in report on Friday, May 13 to "Buy" rating. The rating was maintained by Piper Jaffray with "Overweight" on Friday, July 24. Its down 0.23, from 0.93 in 2016Q3. It dived, as 51 investors sold DFS shares while 284 reduced holdings. Goldman Sachs Grp Inc accumulated 927,179 shares or 0.01% of the stock. The institutional investor owned 6,481 shares of the biopharmaceutical company's stock after selling 12,400 shares during the period.

Zelman Capital Llc holds 8.82% of its portfolio in Andina Acquisition Corp for 589,799 shares. (NASDAQ:GILD). Tctc Hldgs Lc stated it has 5,341 shares or 0.02% of all its holdings. Great Lakes Limited Company has 153,395 shares. Finally, A.R.T. Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter valued at $5,256,000. 990,520 were reported by Clearbridge Ltd Llc. 248,322 were reported by Clough Cap Prtnrs Limited Partnership. Morgan Stanley reported 153,744 shares or 0% of all its holdings. Apriem Advsr accumulated 71 shares. Ameriprise Financial, Minnesota-based fund reported 402,716 shares. Md Sass Investors Ser holds 0.2% or 50,700 shares.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $46,351 activity. Therefore 25% are positive. Discover Financial Services had 56 analyst reports since July 24, 2015 according to SRatingsIntel. Citigroup initiated Gilead Sciences, Inc.

The stock now shows its YTD (Year to Date) performance of 2.43 percent, whereas its Weekly performance stands at -0.74%. The company was upgraded on Wednesday, March 2 by Buckingham Research. The consensus rating is 2.5, suggesting the market has given up on the stock. The rating was maintained by Wood with "Buy" on Tuesday, April 11.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL